Table 3.
Clinical features of patients with normal BCVA for age and under-normal range for age
| BCVA | |||
|---|---|---|---|
| Normal for age | Under-range for age | p-value | |
| Eyes, n (%) | 37(55.2) | 30(44.8) | – |
| Follow-up duration, months | 84.3 ± 52.3 | 88.0 ± 66.5 | .800 |
| Gender, M/F (%) | 64.9/35.1 | 36.7/63.3 | .028 |
| Ethnicity, Caucasian/African (%) | 91.9/8.1 | 86.7/13.3 | .691 |
| Laterality, bi/unilateral (%) | 86.5/13.5 | 83.3/16.7 | .743 |
| PCG, neonatal/infantile (%) | 35.1/64.9 | 66.7/33.3 | .014 |
| Number of surgeries | 1 (1–1) | 2 (1–2) | < .001 |
| IOP at baseline (mmHg) | 22.8 ± 4.3 | 23.4 ± 3.6 | .594 |
| IOP at final follow-up (mmHg) | 12.5 ± 2.9 | 13.5 ± 3.0 | .178 |
| AL at baseline (mm) | 21.85 ± 1.99 | 21.87 ± 2.83 | .967 |
| AL at final assessment (mm) | 23.73 ± 2.01 | 25.43 ± 2.30 | .001 |
| Corneal opacity at baseline, Yes/No (%) | 59.5/40.5 | 86.7/13.3 | .016 |
| CDR at baseline | 0.44 ± 0.17 | 0.51 ± 0.21 | 0.231 |
|
Drugs at baseline, Yes/No (%) Number of drugs |
13.5/86.5 0(0) |
30/70 0(0–1) |
.134 |
|
Drugs at last FUP, yes/no (%) number of drugs |
13.5/86.5 0(0) |
45/55 1.5(0–2) |
< .001 |
| Strabismus, yes/no (%) | 13.5/86.5 | 43.3/56.7 | .011 |
| SER, D | 3.28 ± 3.04 | 6.07 ± 3.89 | .003 |
BCVA best-corrected VA, IOP, intraocular pressure, AL axial length, CDR cup-to-disk ratio, SER spherical equivalent of refraction